📌 Key Takeaways
- Topic: What Is Mesoporous Silica? Structure, Pore Size and Applications in Drug Delivery and Catalysis
- Keywords: silica for powder coatings
- Published: 2026-11-20 04:43:18
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
What Is the Refractive Index of Silica? Values for Fused Silica, Quartz and Amorphous Silica
- Is There a Quartz Sand Shortage? Causes, Impact and Supply Outlook
- Silica for Epoxy Molding Compound (EMC): Spherical Silica Specs and Selection
- An, D. et al. NIR‐II responsive inorganic 2D nanomaterials for cancer photothermal therapy: recent advances and future challenges. Adv. Funct. Mater. 31, 2101625 (2021). Piece CAS Google Scholar
- Silicon Dioxide Side Effects: What You Need to Know
- Thierry, B. et al. Electrostatic self-assembly of PEG copolymers onto porous silica nanoparticles. Langmuir 24, 8143-8150 (2008). Post CAS PubMed Google Scholar
- Silica for Rubber: Reinforcement Benefits, Grades and Compounding Tips
Syloid Silica: Matting, Excipient and Food Grades Explained, with Alternatives
What is silica (SiO₂)?
high purity quartz sand
What is the difference between fumed silica and precipitated silica?
silica TDS
What drives silica raw material prices?
CMP slurry silica Due to the essential function of MSNs in the biomedical field, the timeline of some key achievements involving MSNs is presented in Fig. 3. Comparable to MCM-41, Santa Barbara Amorphous-15 (SBA-15) is also demonstrated to be another really promising nanomaterial in the biomedical field, which is a highly stable mesoporous silica sieve reported by scientists from the University of California at Santa Barbara in 1998. 47 Several years later, the first instance of biomedical applications involving mesoporous silica for drug delivery is reported. 48 MCM-41 is revealed to have the talent to load and deliver the anti-inflammatory drug, ibuprofen, with a weight percent ratio of 30%. 48 In the same year, researchers from two different research groups both reported that the particle size of MCM-41 could be tuned to the nanoscale, 49, 50 and its morphology could also be precisely designed. 50 These findings have greatly encouraged researchers to discuss the potential biomedical applications of MSNs. In 2003, Lai et al. explored the feasibility of MCM-41-type MSNs in controlled-release delivery systems, in which they used cadmium sulfide (CdS) NPs as chemically removable caps to encapsulate drug molecules into the pore channels of MSNs. 51 Subsequently, the disulfide bond-reducing molecules served as triggers to control the stimuli-responsive release of drug molecules including vancomycin and adenosine triphosphate. 51 In the meantime, the same research group also utilized polyamidoamines to modify the surface of MCM-41-type MSNs, and constructed a novel gene transfection system in 2004, which is the first study of the uptake behavior about MSNs into the eukaryotic cells. 52 Afterwards, Lin et al. developed fluorescein-labelled hexagonal crystal-like MSNs with a size of 110 nm as cell marker. 53 To fully exploit the physicochemical properties of MSNs and their potential for biomedical applications, in 2008, Liong et al. loaded superparamagnetic iron oxide into the internal pores of MSNs and subjected MSNs to phosphonate coating, targeting ligand modification and anti-cancer drug encapsulation, resulting in a multifunctional silica-based nanoplatform that can be used for imaging, targeting and drug delivery. 54 Since the degradability of MSNs is critical to the growth of nanoformulations with high safety, researchers continue to discuss the degradation behavior and mechanisms of MSNs. In 2010, a three-state degradation process of MSNs was proposed, which presented a new understanding of the degradation kinetic mechanism of MSNs that differs markedly from that of traditional non-porous silica-based materials. 55 Apart from, Lin et al. systematically shown the impact of MSNs with diverse particle size, pore structure and surface modification on hemolytic activity in 2010. 56 This pioneering work delivers advice for understanding the toxic influences of MSNs in vivo. In 2011, Cornell dots, which are silica-based hybrid NPs with a size of 6-10 nm, become the first FDA-approved nanoformulation for a first-in-human clinical trial. 57 The first-in-human clinical trial of 124 I-labelled Cornell dots showed that they can be applied to diagnose and stage tumors including melanoma and malignant brain cancer. 58 Furthermore, to obtain MSNs with rapid biodegradability, Zhao's group developed a biphase stratification method for preparing monodispersed three-dimensional dendritic MSNs (3D-dendritic MSNs). The as-prepared 3D-dendritic MSNs can degrade completely in the simulated biological medium within 24 h. 59 Over the past few years, with the outbreak and spread of coronavirus SARS-CoV-2, nanotechnology based on MSNs against coronavirus infection has also developed. In 2020, Balagna et al. conducted preliminary antiviral test toward SARS-CoV-2 by using the silver nanocluster/silica nanocomposite deposited onto facial masks. 60 In another work, a FDA-approved antiviral drug, niclosamide (NIC), was encapsulated into MSNs, followed by the coating with Tween 60. The MSNs-based nanocomposite was demonstrated to be a potential oral formulation for SARS-CoV-2. 61
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.